Oxigene regains compliance with NASDAQ listing rule Oxigene announced that on January 14 Nasdaq notified the company that it regained compliance with the minimum $1.00 per share closing bid price requirement for continued listing. As a result of satisfying the minimum bid price requirement, this matter is now closed.
OXiGENE announces $10M at-the-market registered direct offering OXiGENE announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of $10< of registered shares of OXiGENE common stock in an at-the-market direct offering at a price of $1.7125 per share. For each share of common stock purchased, investors will receive a warrant to purchase one half of a share of common stock at an exercise price of $1.7125 per share, which are exercisable immediately and expire five years from the date of issuance. H.C. Wainwright & Co. acted as the exclusive placement agent in connection with this offering.